Xin Yuan, MD, DSc

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2066

xyuan@bidmc.harvard.edu

Beth Israel Deaconess Medical Center
Phone: (617) 735-2066

xyuan@bidmc.harvard.edu

Xin Yuan, MD, DSc

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

Assistant Professor, Medicine, Harvard Medical School
Assistant Professor, Medicine, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Prostate Cancer, Member

Research Abstract

The major focus of the lab is on the molecular basis of cancer development and progression. One of the focus areas is the molecular and functional contribution of the SOX9 developmental factor in prostate and breast cancers. We have discovered that SOX9 is an important convergence node of multiple signal pathways that are critical for the development and oncogenesis. These signal pathways include androgen receptor, WNT, and ERG signals. SOX9 critically mediating these oncogenic signals and enhances tumor formation, invasion, treatment resistance, and angiogenesis. The SOX9 signal pathway represents novel therapeutic targets for intervention and biomarkers for disease progression.

Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, Voznesensky O, Xie F, Zhang X, Yuan X, Balk SP. WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Res 2023. PubMed
Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SP. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res 2022; 82:1518-1533. PubMed
de P Mendes R, Yuan X, Genega EM, Xu X, da F Costa L, Comin CH. Gland context networks: A novel approach for improving prostate cancer identification. Comput Med Imaging Graph 2021; 94:101999. PubMed
Liang J, Wang L, Poluben L, Nouri M, Arai S, Xie L, Voznesensky OS, Cato L, Yuan X, Russo JW, Long HW, Brown M, Chen S, Balk SP. Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Lett 2021; 519:172-184. PubMed
Han D, Owiredu JN, Healy BM, Li M, Labaf M, Steinfeld JS, Patalano S, Gao S, Liu M, Macoska JA, Zarringhalam K, Siegfried KR, Yuan X, Rebbeck TR, Cai C. Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression. Cancer Res 2021. PubMed
He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med 2021; 27:426-433. PubMed
Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PG. Genomic Characteristics of Myeloproliferative Neoplasms in Patients Exposed to Ionizing Radiation following the Chernobyl Nuclear Accident. Am J Hematol 2018. PubMed
Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 2018; 78:5203-5215. PubMed
Sonzogni O, Haynes J, Seifried LA, Kamel YM, Huang K, BeGora MD, Yeung FA, Robert-Tissot C, Heng YJ, Yuan X, Wulf GM, Kron KJ, Wagenblast E, Lupien M, Kislinger T, Hannon GJ, Muthuswamy SK. Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo. PLoS Biol. 2018; 16:e2004049. PubMed
Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan X. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest 2016. PubMed
Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013; 123:1109-22. PubMed

Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan X. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J Biol Chem 2013; 288:6478-87. PubMed
Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan X. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res 2008; 68:1625-30. PubMed
Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 2007; 67:528-36. PubMed

Hide

Xin Yuan, MD, DSc

Beth Israel Deaconess Medical Center

Similar Members

Similar Members

Xin Yuan, MD, DSc

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

DF/HCC PROGRAM AFFILIATION

Research Abstract

Publications from Harvard Catalyst Profiles

Similar Members

Similar Members